

Novel Insights Into the Genetics of Intracerebral Hemorrhage

Alessandro Biffi, MD; Christopher D. Anderson, MD; Guido J. Falcone, MD; Brett Kissela, MD; Bo Norrving, MD; David L. Tirschwell, MD, MSc; Magdy Selim, MD; Devin L. Brown, MD, MS; Scott L. Silliman, MD; Bradford B. Worrall, MD, MSc; James F. Meschia, MD; Chelsea S. Kidwell, MD; Joseph P. Broderick, MD; Steven M. Greenberg, MD, PhD; Jaume Roquer, MD, PhD; Arne Lindgren, MD; Agnieszka Slowik, MD, PhD; Reinhold Schmidt, MD; Daniel Woo, MD, MSc; Jonathan Rosand, MD, MSc; on behalf of the International Stroke Genetics Consortium

Isolated observations suggest a role for genetic risk factors in intracerebral hemorrhage (ICH). However, no systematic evaluation on the role of DNA variation in ICH has been attempted to date. We performed a large-scale genetic association study of 2189 ICH cases and 4041 controls. We included 1104 ICH cases attributable to cerebral amyloid angiopathy (CAA-ICH) and 1085 hypertensive ICH cases (H-ICH). Recently developed methods were used to determine heritability from unrelated ICH cases and controls. We also analyzed clinical ICH phenotypes: these included admission ICH volume (quantified on computed tomography scan), hematoma expansion (on follow-up computed tomography scan), and functional independence and mortality at 90 days post-ICH. We tested single variants across the entire genome (at genome-wide significance threshold of $P < 5.0 \times 10^{-8}$). We also tested 2 genetic risk scores, summarizing the effect of known hypertension and Alzheimer disease risk loci. We estimated heritability of 45% for ICH, 70% for the CAA-ICH subset, and 35% for the H-ICH subset. *Apolipoprotein E* $\epsilon 2/\epsilon 4$ were associated with CAA-ICH at genome-wide significance levels (odds ratio [OR]=1.82; $P=6.6 \times 10^{-10}$ and OR=2.20; $P=2.4 \times 10^{-11}$, respectively). $\epsilon 2$ was also associated with larger admission CAA-ICH volume (hematoma size increase=5.3 cc per allele copy; $P=0.004$) and with CAA-ICH hematoma expansion (OR=2.72; $P=0.009$). We also found associations between *apolipoprotein E* $\epsilon 2$ and functional independence

(OR=0.68; $P=0.009$) and mortality (OR=1.57; $P=0.021$) after CAA-ICH. A genetic risk score summarizing the effects of all known Alzheimer disease loci was associated with CAA-ICH (OR=1.22 for each of the 11 incorporated variants; $P=2.2 \times 10^{-5}$). This was largely mediated by one variant in the *CRI* gene (OR=1.61; $P=8.0 \times 10^{-4}$), which was also associated with CAA-ICH recurrence (hazard ratio=1.35; $P=0.024$). A genetic risk score summarizing the effects of all known hypertension loci was associated with the risk of H-ICH (OR=1.18 of each of 40 incorporated variants; $P=0.001$) but not CAA-ICH ($P=0.34$). We provided the first quantitative assessment of ICH heritability. We also identified apolipoprotein E $\epsilon 2/\epsilon 4$ as risk factors for CAA-ICH at genome-wide level. $\epsilon 2$ is also associated with CAA-ICH volume and outcome. Another Alzheimer disease-related locus, *CRI*, also influences CAA-ICH incidence and recurrence. Conversely, hypertension loci play a role in H-ICH risk but not in CAA-ICH. Our results confirm the suspected clinical and etiopathogenetic heterogeneity of ICH: amyloid-related processes influence incidence and clinical course of CAA-ICH, whereas hypertension genetics play a major role in H-ICH.

Disclosures

None.

KEY WORDS: ApoE ■ Cerebral Amyloid Angiopathy ■ hypertension ■ intracerebral hemorrhage ■ population genetics

Received April 23, 2013; accepted April 24, 2013.

From the Hemorrhagic Stroke Research Group (A.B., C.D.A., G.J.F., S.M.G., J.R.), Division of Neurocritical Care and Emergency Neurology, Department of Neurology (A.B., C.D.A., G.J.F., J.R.), and Center for Human Genetic Research (A.B., C.D.A., G.J.F., J.R.), Massachusetts General Hospital, Boston, MA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (A.B., C.D.A., G.J.F., J.R.); Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH (B.K., J.P.B., D.W.); Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden (B.N., A.L.); Department of Neurology, Skåne University Hospital, Lund, Sweden (B.N., A.L.); Stroke Center, Harborview Medical Center, University of Washington, Seattle, WA (D.L.T.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA (M.S.); Stroke Program, Department of Neurology, University of Michigan Health System, Ann Arbor, MI (D.L.B.); Department of Neurology, University of Florida College of Medicine, Jacksonville, FL (S.L.S.); Department of Neurology and Public Health Sciences, University of Virginia Health System, Charlottesville, VA (B.B.W.); Department of Neurology, Mayo Clinic, Jacksonville, FL (J.F.M.); Department of Neurology, Georgetown University Medical Center, Washington, DC (C.S.K.); Neurovascular Research Unit, Department of Neurology (J.R.) and Program in Inflammation and Cardiovascular Disorders (A.S.), Institut Municipal d'Investigació Mèdica-Hospital del Mar, Barcelona, Spain; Neurovascular Research Unit, Department of Neurology and Program in Inflammation and Cardiovascular Disorders, Universitat Autònoma de Barcelona, Barcelona, Spain (J.R., R.S.); Department of Neurology, Jagiellonian University Medical College, Krakow, Poland (A.S.); and Department of Neurology, Medical University of Graz, Graz, Austria (R.S.).

Correspondence to Alessandro Biffi, MD, Massachusetts General Hospital, CPZN 6818, Simches Bldg, 185 Cambridge St, Boston, MA 02114. E-mail biffi@chgr.mgh.harvard.edu

(*Stroke*. 2013;44[suppl 1]:S137.)

© 2013 American Heart Association, Inc.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.113.001912

Novel Insights Into the Genetics of Intracerebral Hemorrhage

Alessandro Biffi, Christopher D. Anderson, Guido J. Falcone, Brett Kissela, Bo Norrving, David L. Tirschwell, Magdy Selim, Devin L. Brown, Scott L. Silliman, Bradford B. Worrall, James F. Meschia, Chelsea S. Kidwell, Joseph P. Broderick, Steven M. Greenberg, Jaume Roquer, Arne Lindgren, Agnieszka Slowik, Reinhold Schmidt, Daniel Woo and Jonathan Rosand
on behalf of the International Stroke Genetics Consortium

Stroke. 2013;44:S137

doi: 10.1161/STROKEAHA.113.001912

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://stroke.ahajournals.org/content/44/6_suppl_1/S137

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Stroke* is online at:
<http://stroke.ahajournals.org/subscriptions/>